Free delivery on all NHS prescriptions — order now
- Home
- Weight Loss
- Weight Loss Treatments
- Mounjaro KwikPen (tirzepatide injection)
Mounjaro KwikPen (tirzepatide injection)
Images for illustrative purposes only
Mounjaro KwikPen (tirzepatide) is a once-weekly, prescription-only medicine for weight management and type 2 diabetes. As a dual GIP and GLP-1 receptor agonist, it works on two gut-hormone pathways to help regulate appetite and blood sugar. Each multi-dose KwikPen holds four weekly doses, and treatment is supplied only after an online consultation with our GPhC-registered pharmacy.
- Assessed: By a GMC-registered prescriber.
- Dosing: Once-weekly pre-filled KwikPen.
- Verified: FitXpress AI body scan BMI check.
- Delivery: Sent in protective packaging.
More information
An overview from our Superintendent Pharmacist
At a glance
- Mounjaro KwikPen delivers tirzepatide, a first-in-class dual GIP and GLP-1 receptor agonist, as a once-weekly injection under the skin.
- It is licensed for weight management in obesity (or overweight with a weight-related condition) and for type 2 diabetes.
- One KwikPen is a multi-dose pen holding four weekly doses (a one-month supply), available in strengths from 2.5 mg to 15 mg.
- The dose is increased gradually (dose titration) to reduce side effects, most of which are digestive and usually settle.
- Mounjaro is prescription-only, so treatment follows a clinical assessment. It is not sold like an ordinary product.
"Mounjaro has changed the conversation around weight management because tirzepatide works on two appetite and blood-sugar pathways rather than one. In practice, the people who do best start low, increase slowly, and treat it as one part of a plan that includes diet, activity and regular review. Because it is a prescription-only medicine with real precautions, from how it interacts with the contraceptive pill to who should avoid it, the law rightly requires a proper assessment first. If your weight is affecting your health, or your type 2 diabetes is not well controlled, I would encourage you to start a confidential consultation so our prescribers can check whether it is safe and suitable for you."
Rachael Clarke MRCPharm, Superintendent PharmacistHow does Mounjaro (tirzepatide) work?
Mounjaro works by activating two natural gut hormone receptors at the same time, which is what makes it different from single-hormone treatments. Its active ingredient, tirzepatide, is a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. These are known as incretin hormones, and this combined action is why tirzepatide is often described as a "twincretin".
By stimulating both receptors, tirzepatide slows the rate at which the stomach empties, reduces appetite and food cravings, increases the feeling of fullness, and improves the body's insulin response. A clinical pharmacology study found that tirzepatide improves insulin sensitivity and the function of insulin-producing beta cells.1 Together these effects lower blood sugar and help reduce the calories you take in, supporting weight loss alongside a reduced-calorie diet and more physical activity.
The key difference from a single-hormone GLP-1 receptor agonist such as semaglutide (the ingredient in Wegovy and Ozempic) is that semaglutide acts on the GLP-1 pathway alone, whereas tirzepatide adds GIP activity. Both are established treatment options, and the right one for you is a clinical decision.
The Mounjaro KwikPen and dosing schedule
The Mounjaro KwikPen is a multiple-dose, pre-filled pen that contains four once-weekly doses, giving a one-month supply at a single strength. You give yourself one subcutaneous (under the skin) injection each week, on the same day, into the abdomen, thigh or the back of the upper arm, rotating the site each time. This multi-dose KwikPen is the device supplied in the UK and differs from single-dose pens that hold only one dose each.
Mounjaro is started at a low dose and increased in steps, a process called dose titration. Titrating slowly gives your body time to adjust and helps limit digestive side effects. Treatment begins at 2.5 mg once weekly for four weeks, then increases to 5 mg, after which the dose can be increased by 2.5 mg at a time, no sooner than every four weeks, until you reach your maintenance dose.
| Stage | Dose | When |
|---|---|---|
| Starting dose | 2.5 mg | Weeks 1 to 4 (to help your body adjust) |
| First step up | 5 mg | From week 5 (a maintenance dose) |
| Further steps | 7.5 mg, then 10 mg | Increase by 2.5 mg no sooner than every 4 weeks |
| Higher steps | 12.5 mg, then 15 mg | Only if needed and tolerated |
| Maintenance doses | 5 mg, 10 mg or 15 mg | Maximum dose is 15 mg once weekly |
Strengths available are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. The starting 2.5 mg dose is designed to help you tolerate treatment and is not intended for lasting blood-sugar or weight control. If you miss a dose, you can take it within four days; if more than four days have passed, skip that dose and take the next one on your usual day. Your prescriber will confirm the right schedule for you.
How to store Mounjaro KwikPen
Keep new Mounjaro KwikPens in a refrigerator at 2 to 8 degrees Celsius until you start using them. Once you have taken the first dose from a pen, you can keep it unrefrigerated at or below 30 degrees Celsius for up to 30 days, which covers everyday use and short trips. After 30 days, throw the pen away, even if some medicine is left. Do not freeze Mounjaro, and do not use a pen that has been frozen. Keep it in the original carton to protect it from light. Your treatment is sent out in protective packaging, and you should follow the storage advice in the Patient Information Leaflet supplied with your pen.
Who can be prescribed Mounjaro?
Mounjaro can be prescribed for adults for weight management, and for adults and some younger people for type 2 diabetes, when a prescriber judges it appropriate. For weight management, it is licensed as an adjunct to a reduced-calorie diet and increased activity for adults with:
- A BMI of 30 kg/m² or above (obesity); or
- A BMI of 27 to under 30 kg/m² (overweight) with at least one weight-related health condition, such as high blood pressure, raised cholesterol (dyslipidaemia), obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes.
For type 2 diabetes, Mounjaro is used to improve blood sugar (glycaemic) control, either on its own when metformin is unsuitable, or alongside other diabetes medicines. People from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds are assessed at lower BMI thresholds, because they face weight-related health risks at a lower BMI. Suitability always depends on your full medical history, not BMI alone.
Can you get Mounjaro on the NHS?
Yes, some people can now get tirzepatide for weight management on the NHS, but access is being phased in. NICE recommended tirzepatide for weight management in its technology appraisal TA1026, published on 23 December 2024, and NHS specialist weight management services could prescribe it from March 2025. NHS England began rolling it out through primary care in June 2025, starting with people who have the highest BMI and the most weight-related conditions. Set priority groups cover the first 3 years, and NICE allows up to 12 years for everyone it recommends tirzepatide for to have access.
Because the NHS phases prioritise the highest-need groups first, many adults who meet the licensed criteria but not yet the current NHS phase choose a private online consultation. This is where a regulated pharmacy service like Mail My Meds provides a lawful, prescriber-led route to assessment and, where appropriate, treatment.
How the online consultation works
You access Mounjaro through Mail My Meds by completing a medical consultation first, never by adding it straight to a basket. Prescription treatment is only supplied after a GMC-registered prescriber has assessed you, which keeps you safe and keeps the process within UK rules.
- Complete the online consultation. Answer confidential questions about your weight and BMI, medical history, current medicines and general health. It usually takes only a few minutes.
- A prescriber reviews your answers. A GMC-registered prescriber checks whether treatment is safe and suitable and, if so, at what starting dose. They may ask a follow-up question if needed.
- Suitable treatment is dispensed and delivered. If Mounjaro is appropriate, our UK pharmacy dispenses it and sends it out in protective packaging. If it is not suitable, we explain why and suggest safer alternatives.
How FitXpress Supports A Safe Consultation
FitXpress is the Mail My Meds tool that helps you start your consultation and gather what a prescriber needs to assess you, but it supports our clinicians rather than replacing them. A registered prescriber reviews your case, independently confirms your weight, height and BMI, and makes the final decision on whether to prescribe. The steps below show how it works.
How FitXpress works
- Start: Tell us which type of treatment you are enquiring about, so we can ask the right questions.
- Consult: Complete a confidential medical questionnaire about your health and history.
- Scan: Upload two photos (fully clothed, in an A-pose) to help estimate your measurements as part of your assessment.
- Clinical review: A GMC-registered prescriber reviews your information, independently verifies your BMI, and issues a prescription only if treatment is appropriate and safe for you.
Top tips for a clear scan:
- Wear fitted rather than baggy clothing, so your shape is easier to see.
- Stand in a well-lit area against a plain, light-coloured wall.
- Use the voice assistant feature if you are taking the photos yourself.
- Make sure your whole body is visible in the frame.
How does Mounjaro compare with other weight management treatments?
Mounjaro is one of several options, and the best choice depends on your BMI, your health and how much support you need. Lifestyle change is the foundation of every plan, while medicines and surgery are added when clinically appropriate. The table below compares the main routes as balanced information.
| Option | How it works | Typically considered for | How it is accessed |
|---|---|---|---|
| Diet and lifestyle changes | Creates a calorie deficit and improves diet quality, activity and sleep | Everyone; the first-line foundation | Self-managed, NHS advice or structured programmes |
| Orlistat | A lipase inhibitor that reduces how much dietary fat the body absorbs | Adults meeting BMI thresholds, with a lower-fat diet | Pharmacy (lower-strength Alli) or prescription (Xenical) |
| Single-hormone GLP-1 medicine (e.g. semaglutide: Wegovy injection or Wegovy pill) | Activates the GLP-1 receptor to slow digestion and reduce appetite | BMI 30+, or 27+ with a weight-related condition | Online consultation and clinical assessment (prescription-only) |
| Mounjaro (tirzepatide) | Dual GIP and GLP-1 receptor agonist; acts on two hormone pathways | BMI 30+, or 27+ with a weight-related condition; also type 2 diabetes | Online consultation and clinical assessment (prescription-only) |
| Bariatric (weight-loss) surgery | Alters the digestive system to reduce intake or absorption | BMI 40+, or 35+ with serious comorbidities | NHS or private specialist referral |
In the phase 3 SURMOUNT-1 trial, published in the New England Journal of Medicine, tirzepatide produced substantial average weight loss alongside diet and activity in adults with obesity.2 A later head-to-head study, SURMOUNT-5, reported greater average weight loss after 72 weeks with tirzepatide (20.2%) than with the single-hormone medicine semaglutide (13.7%) in adults without diabetes.3 In type 2 diabetes, the SURPASS-2 trial found greater reductions in HbA1c (blood sugar) and body weight over 40 weeks with tirzepatide than with semaglutide 1 mg,4 and SURMOUNT-2 showed meaningful weight loss in people who have both obesity and type 2 diabetes.5
Tirzepatide has also been studied for weight-related conditions. The SURMOUNT-OSA trial reported improvements in obstructive sleep apnoea,6 and the SUMMIT trial examined its effects in heart failure with preserved ejection fraction in people with obesity. Individual results vary, and your prescriber can explain what is realistic for you. Among prescription options, demand for tirzepatide has grown quickly because of its dual mechanism, while orlistat remains a long-established pharmacy and prescription choice.
Read more: Wegovy vs Mounjaro · Wegovy Pill vs Mounjaro · Weight-Loss Tablets vs Injections · Weight loss treatments compared
What are the common side effects of Mounjaro?
The most common side effects of Mounjaro affect digestion and are usually mild to moderate, easing over time as the dose is increased slowly. Very common effects, affecting more than 1 in 10 people, include:
- Nausea
- Diarrhoea
- Vomiting
- Constipation
- Abdominal (tummy) pain
Common effects (affecting up to 1 in 10 people) include reduced appetite, dizziness, indigestion, bloating, burping, wind, reflux, gallstones, hair loss, tiredness, injection site reactions, a faster heart rate, and low blood sugar (hypoglycaemia) when Mounjaro is taken with a sulfonylurea or insulin. Less commonly, more serious problems such as inflammation of the pancreas (pancreatitis) or gallbladder can occur; large studies of this class of medicine have examined gallbladder and biliary events in more detail. Always read the Patient Information Leaflet for the full list, and report severe, persistent or unusual symptoms to your prescriber or pharmacist.
"Most people who get side effects notice them early and around dose increases, and they are usually manageable with simple measures like smaller, lower-fat meals and good hydration. What we never want is for someone to push through severe or persistent tummy pain, so tell us if that happens rather than waiting."
Rachael Clarke MRCPharm, Superintendent PharmacistWarnings and precautions
Mounjaro is a prescription-only medicine because it has important precautions, and some people should not use it. Tell your prescriber about your full medical history, and do not start treatment without an assessment if any of the following apply.
- Pancreatitis: tell your prescriber if you have ever had inflammation of the pancreas. Seek urgent help for severe, persistent tummy pain that may spread to your back.
- Gallbladder problems: treatment can increase the risk of gallstones and gallbladder inflammation.
- Severe digestive disease: Mounjaro has not been studied in severe gastrointestinal conditions such as severe gastroparesis and is used with caution.
- Diabetes and low blood sugar: the risk of hypoglycaemia rises when combined with a sulfonylurea or insulin, so those doses may need reducing.
- Dehydration and kidneys: nausea, vomiting or diarrhoea can lead to dehydration and, rarely, kidney problems, so keep well hydrated.
- Diabetic eye disease: if you have diabetic retinopathy, your prescriber will advise on monitoring.
- Thyroid: tell your prescriber about any personal or family history of medullary thyroid cancer or MEN 2 syndrome.
- Surgery and anaesthesia: because Mounjaro slows stomach emptying, tell any healthcare team about it before a general anaesthetic or deep sedation.
Mounjaro should not be used in pregnancy, and you should stop it at least one month before trying to conceive because it stays in the body for some time. It is contraindicated if you are allergic to tirzepatide or any ingredient in the pen. Discuss breastfeeding with your prescriber.
Contraception warning: tirzepatide can reduce how well oral contraceptives (the pill) are absorbed, especially when you start and after each dose increase. If you could become pregnant and use the pill, switch to a non-oral method or add a barrier method such as condoms for four weeks after starting Mounjaro and for four weeks after each dose increase. Your prescriber can talk you through the right approach.
Safety warning: only obtain Mounjaro from a GPhC-registered pharmacy after a proper consultation. The MHRA has warned that counterfeit and unlicensed weight-loss products are being sold online and through social media, and these can be dangerous. Never buy prescription medicines from unregulated sellers, social media or individuals.
What do people experience on treatment?
People often describe a noticeable reduction in appetite and food "noise" within the first few weeks, along with feeling full sooner at meals. Many also report early digestive side effects around the start of treatment and after dose increases, which usually settle. The most consistent theme from real-world use is that Mounjaro works best when it supports lasting changes to eating and activity, rather than replacing them.
It also helps to know that weight management is long term. The SURMOUNT-4 trial found that stopping tirzepatide led to weight being regained, while continuing treatment maintained the weight loss.7 That is why prescribers focus on building sustainable habits and regular review alongside the medicine. Your experience is individual, and staying in contact with your prescriber helps you get the most from treatment safely.
Lifestyle and risk factors
Lifestyle factors strongly influence weight, and they are also where change makes the biggest long-term difference, with or without medication. Mounjaro is licensed as an adjunct to a reduced-calorie diet and increased physical activity, not as a stand-alone fix. The main areas to focus on are:
- Diet quality and portion size: a balanced, nutritionally complete eating pattern with plenty of vegetables, fibre and lean protein, and fewer energy-dense foods and sugary drinks.
- Physical activity: UK guidance recommends at least 150 minutes of moderate activity each week, plus muscle-strengthening on two days.
- Alcohol, sleep and stress: alcohol adds hidden calories, and poor sleep or ongoing stress disrupt the hormones that control hunger.
Non-modifiable factors such as genetics, age and some medical conditions also play a part. They do not make weight loss impossible; they simply mean the right support and, where appropriate, treatment can help level the playing field.
When should you see a doctor?
You should get medical advice promptly if you develop severe or persistent tummy pain, especially if it spreads to your back and comes with vomiting, as this can be a sign of pancreatitis. Seek urgent help for signs of a serious allergic reaction, such as swelling of the face, lips or throat or difficulty breathing.
More generally, speak to a doctor or pharmacist if excess weight is affecting your health or mobility, if your type 2 diabetes is not well controlled, or before starting any treatment if you have an existing health condition or take regular medicines. Any rapid, unexplained weight loss should be checked in its own right.
How to start treatment with Mail My Meds
To start, complete our confidential online consultation and let a GMC-registered prescriber assess whether Mounjaro is right for you. The process is designed to be quick, private and safe.
- Check your BMI. Have your height and weight ready so you can complete the assessment accurately.
- Complete the online consultation. Answer questions about your health, medical history and current medicines, including any contraception.
- Get a prescriber's decision. A clinician reviews your answers and confirms whether treatment is suitable and at what starting dose.
- Receive your delivery. If appropriate, your treatment is dispensed by our UK pharmacy and sent in protective packaging. When it arrives, put it in the fridge until you start using it, as described above.
Are there non-medical or alternative treatments?
Yes. Non-medical approaches are the foundation of weight management and are recommended for everyone, whether or not they also use medication. The most effective plans combine dietary change, more physical activity and behavioural support so those changes last.
- Balanced, sustainable diet: reducing calories through a nutritionally balanced eating pattern rather than crash dieting.
- Regular physical activity: a mix of everyday movement, structured exercise and strength work.
- Behavioural support: goal-setting, self-monitoring and techniques such as cognitive behavioural approaches. UK research including the DiRECT trial showed that structured, lower-calorie programmes can even drive type 2 diabetes into remission for some people.8
- Structured programmes: NHS and community weight management services, including the NHS Digital Weight Management Programme for eligible adults.
- Other medicines and surgery: orlistat as a pharmacy or prescription option, and bariatric surgery for people with the highest BMI or most serious weight-related conditions.
Frequently asked questions
Is Mounjaro used for weight loss or type 2 diabetes?
Mounjaro (tirzepatide) is licensed for both. It is prescribed for weight management in adults with obesity, or who are overweight with a weight-related condition, alongside diet and activity, and to improve blood sugar control in type 2 diabetes. A prescriber decides which use applies to you during the consultation.
How is Mounjaro different from Wegovy or semaglutide?
Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist, so it acts on two gut-hormone pathways. Semaglutide, the ingredient in Wegovy, acts on the GLP-1 pathway alone. Both slow digestion and reduce appetite, but tirzepatide's dual action is what distinguishes it. Your prescriber advises which is suitable.
How many doses are in a Mounjaro KwikPen?
One Mounjaro KwikPen is a multiple-dose pre-filled pen that contains four once-weekly doses, which is a one-month supply at a single strength. This differs from single-dose pens that hold one dose each. You dial and inject one dose per week, rotating the injection site.
How do you take Mounjaro KwikPen?
Mounjaro is a once-weekly subcutaneous injection, given on the same day each week into the abdomen, thigh or upper arm. Treatment starts at 2.5 mg and increases in 2.5 mg steps no sooner than every four weeks until you reach your maintenance dose, up to a maximum of 15 mg.
How do I get Mounjaro in the UK online?
Mounjaro is a prescription-only medicine, so it cannot be bought off the shelf. With Mail My Meds you complete a confidential online consultation, a GMC-registered prescriber checks whether treatment is safe and suitable, and if appropriate it is dispensed by our UK pharmacy and delivered in protective packaging.
Who is eligible for Mounjaro for weight management?
For weight management, Mounjaro is generally considered for adults with a BMI of 30 or above, or a BMI of 27 or above with a weight-related condition such as high blood pressure, raised cholesterol, prediabetes or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds. A prescriber confirms eligibility.
What are the common side effects of Mounjaro?
The most common side effects are gastrointestinal: nausea, diarrhoea, vomiting, constipation and abdominal pain. These are usually mild to moderate and tend to ease as your body adjusts and as the dose is increased slowly. Always read the Patient Information Leaflet and report severe or persistent symptoms to your prescriber.
Does Mounjaro affect the contraceptive pill?
It can. Tirzepatide may reduce how well oral contraceptives are absorbed, especially when you start treatment and after each dose increase. If you use the pill, switch to a non-oral method or add a barrier method such as condoms for four weeks after starting and for four weeks after each dose increase. Discuss this with your prescriber.
How should Mounjaro KwikPen be stored?
Keep new pens in a refrigerator at 2 to 8 degrees Celsius. Once you have started a pen, you can keep it unrefrigerated at or below 30 degrees Celsius for up to 30 days, then throw it away, even if some medicine is left. Do not freeze it, and keep it in the original carton to protect it from light.
Can I get Mounjaro on the NHS?
Yes, for some people. NICE recommends tirzepatide for weight management, and the NHS is rolling it out in phases through primary care from June 2025, starting with the highest BMI and most weight-related conditions. Many adults who do not yet meet the NHS phase criteria choose a private online consultation instead.
Mounjaro guides
Sources and references
Key studies, trials and reviews
- 1. Thomas MK, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. Journal of Clinical Endocrinology & Metabolism, 2021. pubmed.ncbi.nlm.nih.gov
- 2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022. nejm.org
- 3. Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). New England Journal of Medicine, 2025. In 751 adults with obesity, or overweight with a weight-related condition, and without diabetes, average weight loss at 72 weeks was 20.2% with tirzepatide and 13.7% with semaglutide. nejm.org
- 4. Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine, 2021. In adults taking metformin, HbA1c fell by 2.01 to 2.30 percentage points with tirzepatide 5 to 15 mg and by 1.86 with semaglutide 1 mg over 40 weeks, and body weight fell by 7.6 to 11.2 kg and 5.7 kg. nejm.org
- 5. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). The Lancet, 2023. thelancet.com
- 6. Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). New England Journal of Medicine, 2024. nejm.org
- 7. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA, 2024. jamanetwork.com
- 8. Lean MEJ, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT). The Lancet, 2018. thelancet.com
Further reading and clinical sources
- NICE. Tirzepatide for managing overweight and obesity, technology appraisal TA1026 (23 December 2024). nice.org.uk/guidance/ta1026
- NICE. Overweight and obesity management, guideline NG246 (2025). nice.org.uk/guidance/ng246
- Packer M, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). New England Journal of Medicine, 2025. nejm.org
- Rosenstock J, et al. Efficacy and safety of tirzepatide monotherapy in type 2 diabetes (SURPASS-1). The Lancet, 2021. thelancet.com
- Torgerson JS, et al. XENDOS: orlistat in the prevention of diabetes in obese subjects. Diabetes Care, 2004. pubmed.ncbi.nlm.nih.gov
- British National Formulary (BNF). Tirzepatide. bnf.nice.org.uk
- NHS. Obesity and type 2 diabetes. nhs.uk
- NHS England Digital. Health Survey for England 2024: adults' overweight and obesity. digital.nhs.uk
- MHRA. Warnings on counterfeit and unlicensed weight-loss products. gov.uk/mhra
Our commitment to content accuracy
Our health content is written and reviewed by our team of medical experts and checked against trusted sources such as NICE, the British National Formulary and the NHS. We review our pages regularly to make sure the information stays up to date, accurate and genuinely helpful. If you think something needs updating, please let us know.
Medical disclaimer: This information is provided for general informational purposes only and does not replace individual advice from a qualified healthcare professional. It should not be used to diagnose or treat a health condition, and it is not an advertisement or a recommendation to use any specific medicine. Whether a prescription treatment is suitable for you can only be decided by a prescriber after a clinical assessment. Always read the Patient Information Leaflet supplied with your medicine, and speak to your GP, pharmacist or prescriber for personalised advice. If you feel unwell or have urgent symptoms, contact NHS 111, or call 999 in an emergency.
Content last updated:

